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Abstract: Alveolar bone marrow stromal cells (aBMSCs) play important roles in craniofacial 
wound healing. To establish an easy, efficient and reliable method to harvest aBMSCs, we 
compared three different methods: extraction socket aspiration, osteotomy aspiration and bone 
core digestion. Samples of aBMSC were collected from two groups of subjects. Group 1 (dental 
extraction): after dental extraction, 22.5-gauge needles were used to collect 0.5-1cc marrow 
aspirate. Group 2 (dental implant): during implant surgeries, bone core and 0.5-1cc marrow 
aspirate were obtained from the osteotomy. Samples were cultured in petri dishes and attached 
cells were expanded. The population doubling time (PDT), surface markers, and osteogenic 
differentiation potential of these cells were studied. In total 12 subjects were enrolled in the 
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study. The success rates of generating aBMSCs from extraction socket aspiration, osteotomy 
aspiration and bone core digestion were 42.8% (3/7), 40% (2/5) and 80% (4/5), respectively. 
Cells from extraction socket aspiration had the fastest proliferation rate among the three sample 
types, followed by bone core and osteotomy aspiration, as shown in PDTs and DNA fold 
changes. After isolation and expansion, all the aBMSCs expressed high levels of CD 73, CD90, 
and CD105, however, the expression of CD146 varied among the cells. Cells derived from bone 
core had the highest ALP activity after osteogenic induction, followed by cells from osteotomy 
aspiration, and then extraction aspiration. Taken together, bone core samples obtained during 
implant surgery is a more reliable source for generating aBMSCs and aBMSCs harvested from 
different methods may have different characteristics.    
 
Key words: Stem cell, alveolar bone marrow stromal cells, regeneration, implant therapy.  
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Introduction 
Untreated periodontitis may lead to progressive loss of clinical attachment, followed by 
destruction of the periodontal ligament and the supporting bone around the periodontium which 
may ultimately lead to tooth loss1. Tooth loss is a severe public problem, especially in the elderly 
population, that causes loss of chewing function, malnutrition, esthetic problems and decreased 
life quality. It is estimated that over 240 million people in the industrialized world are missing 
one or more teeth, and 40% of the Western population has lost at least one tooth2. Based on the 
National Health and Nutrition Examination Survey (NHANES) in 2004, seniors over 65 years of 
age lose an average of 10 teeth per person, and 27.7% of them have no remaining teeth2. Dental 
implants have become a standard of care for the replacement of missing teeth and over 1 million 
implants placed annually in the United States.  Although the long term success rate of dental 
implants is over 90%3–6, the clinical outcome of implant therapy is impacted by many systemic 
conditions, such as diabetes7, smoking8 and osteoporosis9,10, and local factors that include 
insufficient alveolar bone volume11.   
Regenerative medicine strives to repair organs and/or tissues affected by chronic disease12. 
Stems cells are applied in regenerative medicine and disease therapeutics, however, the function 
and nature of mesenchymal stem cells (MSCs) have gone through a number of paradigm 
shifts13,14. Currently, it is believed that MSCs contribute to tissue regeneration through two 
important functions; first, the ability to differentiate into distinct end-stage cell types that include 
bone, cartilage, muscle, tendons, ligaments, fat, dermis, and other connective tissues; second, the 
ability to initiate a broad spectrum of bioactive molecules that promote tissue regeneration in 
injured sites15. In regenerative medicine, embryonic stem cells (ESCs), tissue specific progenitor 
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stem cells (TSPSCs), mesenchymal stem cells (MSCs), umbilical cord stem cells (UCSCs), bone 
marrow stem cells (BMSCs), and induced pluripotent stem cells (iPSCs) have been widely 
studied 12. ESCs have been shown to treat spinal cord injuries16, promote macular defect 
recovery and vision restoration17, regenerate liver tissue after injuries18, and restore damaged 
cartilage in athletes19. TSPSCs have been used to regenerate cochlear20, ischemic myocardium21, 
and goblet mucosa in intestine22. UCSCs have been applied to the repair of injured tendons and 
cartilage23, the treatment of Hodgkin’s lymphoma and other cancers24, and the restoration of beta 
cell function in diabetes25. BMSCs have been utilized to treat AIDS26, neurodegenerative 
diseases27, and aplastic anaemia28. iPSCs have been shown to be promising in the treatment of 
diabetes, COPD and liver degeneration29. A shift of viewpoint acknowledges that MSCs affect 
damaged tissue repair through paracrine or cell-to-cell communication to stimulate host cells13.  
MSCs were traditionally isolated from the iliac crest bone marrow, which was first reported by 
Friedenstein in 197630. This method is generally adopted and widely used in regenerative 
medicine. However, the procedure involving iliac crest bone marrow aspiration makes routine 
isolation of MSC for craniofacial regenerative therapy difficult, especially in dental offices31. In 
addition, studies have suggested that site specific differences exist in MSCs derived from iliac 
crest compared to orofacial (maxilla and mandible) origins31. For craniofacial regeneration, cells 
from craniofacial tissues may be more beneficial compared to those from iliac crest32. 
Currently MSCs can be obtained from several different dental tissues33. Periodontal ligament is a 
fibrous and vascular tissue that contains progenitor cells that have features seen in mesenchymal 
stem cells34. MSCs can be harvested from periodontal ligament tissue of surgically extracted 
third molars35. Human dental pulp, apical papilla, and dental follicle are also potential sources 
for MSCs33. Dental tissue derived MSCs can promote craniofacial wound healing including 
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periodontal tissue regeneration. For example, periodontal ligament progenitors were 
demonstrated to enhance bony defect regeneration in animal models36, and improve clinical 
parameters in humans with deep intrabony defects37. Dental pulp stem cells were seen to 
improve mandibular bone defect repair after 3rd molar extraction when delivered in a collagen 
sponge38.  
MSCs derived from alveolar bone (aBMSCs) has emerged as another important stem cell 
population for regenerative dentistry and implant therapy. Such stem cells can be achieved 
through the use of bone cores and/or marrow aspiration during dental extractions or implant 
therapy39. aBMSCs have a better accessibility than other dental MSCs and are considered the 
primary cells responsible for extraction socket healing and implant osseointegration. Therefore, 
better understanding of aBMSCs may provide valuable information regarding important aspects 
of craniofacial and dental wound healing.     
A recent paper by Mason et al. described the standardization and safety of aBMSC isolation40. 
They isolated aBMSCs by alveolar bone marrow aspiration (~0.5cc) from 45 patients. Results 
from in vitro and in vivo experiments clearly demonstrated the reliability of using small volume 
aspiration to extract aBMSCs. However, they only collected samples from implant preparation 
sites, which significantly limits the application of this technique to implant patients only. Tooth 
extraction is a much more widely performed procedure in dentistry. It has been reported that 
aBMSCs may be isolated by bone marrow aspiration from 3rd molar extraction sites31, however, 
it is unknown if this would be as efficient when applied to other extraction sites. It is also not 
clear whether bone marrow aspiration from extraction sites will be as effective as other technique 
such as bone core harvesting. 
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Although the use of MSCs in regenerative medicine is well documented in the literature, 
research pertaining to the use of aBMSCs in periodontal regeneration is limited. Therefore, the 
cellular characteristics of aBMSCs derived from aspiration of the bone marrow from an alveolar 
post extraction sockets are largely unknown.  
The aims of this study were to extract mesenchymal stem cells from alveolar bone and evaluate 
their regenerative potential based on their osteogenic differentiation potential, population 
doubling time, surface marker characteristics and to investigate which method was more 
predictable in isolating MSCs from alveolar ridges. Once a reliable method is established, new 
studies can be developed to investigate the difference in MSCs derived from patients with 
different conditions such as diabetes and smoking.  
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Methods 
Clinical procedures and sample collection 
Approval for the study was granted by Virginia Commonwealth University Institutional Review 
Board (HM20013027). Patients in the Graduate Periodontics department who received routine 
dental extractions or dental implant treatment were screened by their primary provider. Patients 
that qualified for the study based on a checklist of inclusion and exclusion criteria (Figure 1) and 
were willing to participate the study were consented by the study coordinator. The patient then 
received either a dental extraction or implant placement by their primary provider using standard 
operating procedures.  
The following protocols were followed to collect samples during the surgical procedures:  
Group 1 (dental extraction): Following extraction of the tooth, the clinician inserted a 22.5-
gauge needle connected to a heparinized 1cc syringe into the extraction socket, and 
approximately 0.5-1 cc of marrow aspirate (blood) was obtained. The clinician then 
continued with the surgery and post-surgical management based on the clinical situation.  
Group 2 (dental implant): After elevation of a gingival flap at the position where the implant 
was planned to be placed, a bone core of 2×5 mm was harvested with a trephine bur as the 
step of initial osteotomy drilling. The bone core was stored in sterile saline before sending it 
the lab for analyses. Next, a 22.5-gauge needle connected to a 1cc heparinized syringe was 
inserted into the marrow space, and approximately 0.5-1 cc of marrow aspirate was obtained.  
Cell culture 
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Alveolar bone marrow tissue samples were re-suspended in cold minimum essential alpha 
medium (αMEM; Gibco, Carlsbad, CA, USA) and centrifuged at 600 g for 10 min at room 
temperature. The supernatant was removed and the cell pellet was re-suspended in 5 mL aMEM 
with 15% fetal bovine serum (FBS; Gibco). The cell suspensions were then transferred to T-25 
tissue culture flasks and allowed to sit undisturbed without media change for 5 days in a 37°C 
humidified tissue culture incubator at 5% CO2. Non-adherent cells were removed following 5 
days in culture, and medium was changed to aMEM-10% FBS and changed every 2 to 3 days 
thereafter. Once adherent cells reached 80% to 90% (approximately 10-14 days), the aBMSCs 
were then collected and subcultured up to passage 3. Human BMSCs from iliac crest were 
purchased from RoosterBio (Frederick, MD, USA) and cultured in expansion media until they 
were ready to in vitro experiments. Human gingival fibroblasts (HGFs) were primary cells from 
one donor. They were a courtesy of Dr. William Giannobile in University of Michigan and Dr. 
Martha Somerman from NIDCR, and maintained in DMEM with supplements of 10% FBS and 
1% Penicillin-Streptomycin. During the osteogenic experiments, same media were used for all 
the cells including hBMSCs and HGFs.  
Population doubling time (PDT) 
In order to evaluate the aBMSC proliferation and expansion rates in vitro, population doubling 
times were obtained for the samples. The average PDT was calculated between passage 1 (P1) 
and passage 2 (P2). An online website (https://doubling-time.com/compute.php) was used, which 
uses the following formula: 
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Initial concentration = the seeding cell number 
Final concentration = the cell number in the flask at the time of harvest. 
The unit of duration is hour. 
Flow cytometry  
Flow cytometry was performed on samples to evaluate the expression of MSC markers 
according to the Mesenchymal and Tissue Stem Cell Committee of the International Society for 
Cell Therapy (ISCT). CD 73, CD 90, CD 105, CD 146, and CD 45 MSC markers were used. 
aBMSCs were harvested from T75 flasks by 0.25% Trypsin, transferred into tubes, washed with 
DPBS, and incubated with blocking solution. The cells were then incubated with specific 
antibodies conjugated with a fluorochrome or isotype control antibodies for 30-45 minutes. Cells 
were washed extensively at each step. For fluorochrome compensation, antibodies were added to 
UltraComp eBeads (eBioscience) according to manufacturer’s protocol. Analysis was performed 
on BD FACSAria™ II High-Speed Cell Sorter in VCU flow cytometry core. The list of 
antibodies included: 
 PE conjugated anti human CD45 antibody, R&D MSC Marker kit (FMC002)   
 Brilliant Violet 421 conjugated anti human CD73 antibody, #344007, Biolegends, 
San Diego, CA, USA 
 APC conjugated anti human CD90 antibody, R&D MSC Marker kit (FMC002) 
 PE/Cy7 conjugated anti human CD105 antibody, #323217, Biolegends, San Diego, 
CA, USA 
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 Brilliant Violet 711 conjugated anti human CD146 antibody, #323217, Biolegends, 
San Diego, CA, USA 
 PE/Cy7 conjugated anti mouse IgG1 k antibody, #400125, Biolegends, San Diego, 
CA, USA 
 APC conjugated anti mouse IgG2 antibody, R&D MSC Marker kit (FMC002)   
 PE conjugated anti mouse IgG1 antibody, R&D MSC Marker kit (FMC002)   
 
Osteogenic potential  
The osteogenic potential of the samples was evaluated by the level of alkaline phosphatase 
(ALP) activity. Briefly, cells from different donors were cultured in 24-well plates with growth 
media for 24 hours, at which time the media were changed. Full media (DMEM with 10% FBS, 
1% APS) was added to half of the plates. Osteogenic media (full media with the supplements of 
50 µg/ml ascorbic acid, 10 mM β-glycerophosphate, 10 nMdexamethasone) was added to the 
other half of the plates. Media were changed every 3-4 days. At day 0, 3, 7 and 14 days, cells 
were harvested with 200 ul 0.05% Triton X-100. Total cell DNA was measured by Picogreen 
assay (Promega) and protein content were quantified by Pierce BCA protein assay 
(Thermoscientific). The ALP activities of cell lysates were then measured as a function of p-
nitrophenol hydrolysis from p-nitrophenylphosphate at pH 10.2. The results were normalized to 
the total protein contents. 
Statistical analysis 
This was a pilot study to test the feasibility of different techniques, and therefore we were not 
able to perform statistical analysis on some of the experiments such as measuring PDTs. For 
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other in vitro experiment, only one donor was selected from each group. Statistical analysis was 
performed based on the results of 4 technical replicates of each cell type. The results were 
expressed as means ± standard error of the mean (SEM), and graphs were prepared using Graph 
Pad Prism 7.02 (Graph Pad Software, CA, USA). One-way analysis of variance (ANOVA) was 
conducted, followed by Tukey’s multiple-comparison test. P-value smaller than 0.05 was 
considered to be significance. P-values were indicated using asterisks as follows: * (p<0.05), ** 
(p<0.01), *** (p<0.001), **** (p<0.0001). Statistical analysis was not performed in the cell 
surface marker experiment because only one donor was selected in each cell type and there was 
no technical replicate.   
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Figure 1: Inclusion and Exclusion Criteria for patient selection 
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Figure 2: Flowchart summarizing patient selection and treatment groups. 
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 Table 1: Summary of 3 different harvesting techniques   
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Results 
Success rates of generating aBMSCs from different tissue sources 
Bone marrow aspiration samples from extraction sites were collected from 7 subjects and, of 
these, 3 were able to generate aBMSCs (Table 1 and Figure 2). Additionally, in 5 subjects who 
were receiving implant surgeries, bone marrow aspiration samples were collected from 
osteotomy sites and obtained the bone cores. aBMSCs were able to be generated from 3 marrow 
aspiration samples and from 4 bone cores. These cells had similar morphological characteristics, 
which were fibroblastic-like, and spindle-shaped. All of these cells were able to be expanded to 
passage 2 except for one osteotomy aspiration sample. Therefore, the success rates of generating 
aBMSCs from extraction aspiration, osteotomy aspiration and bone core were 42.8% (3/7), 40% 
(2/5) and 80% (4/5), respectively. Bone core samples obtained during implant surgery appeared 
to be the most reliable source for generating aBMSCs. 
Cell proliferation capability 
Cell proliferation capability was further assessed by calculating the PDT and a DNA assay. The 
average PDTs for samples from extraction aspiration, osteotomy aspiration and bone core were 
43.62 h, 54.72 h and 49.46 h, respectively (Table 1). Although no statistical analysis was 
performed due to the small sample size (only 2 samples from osteotomy aspiration), it appeared 
that the proliferation rate of aBMSCs derived from osteotomy aspiration was slower than other 
cells. We selected one subject from each sample type and measured the changes in DNA content 
after expansion. Similarly, we found that cells from extraction aspiration had the fastest 
proliferation rate among the three sample types, followed by bone core and osteotomy aspiration 
(Figure 3 and Figure 4). Similar results were seen both in growth medium (NT) and osteogenic 
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medium (OM). In this experiment, we also used BMSCs from long bone and gingival fibroblasts 
(HGFs) as controls. Interestingly, aBMSCs appeared to grow faster than long bone BMSCs, but 
slower than HGFs (Figure 4).        
MSC characterization by surface markers 
We also identified the cell surface markers by fluorescence-activated cell sorting (FACS) in each 
of the three types of samples. Following isolation and cell expansion (at passage 3), aBMSCs 
derived from extraction aspiration, osteotomy aspiration and bone core expressed high level of 
CD 73 (96.53%-97.89%), CD90 (98.19%-99.80%), and CD105 (85.02%-91.71%) (Table 2). 
Similar results were seen in the BMSCs from long bone and HGFs. However, the expression of 
another MSC marker, CD146, varied significantly among different samples. Long bone BMSCs 
exhibited the largest percentage (93.7%), followed by HGF (80.13%), osteotomy aspiration 
(75.02%), bone core (62.15%) and extraction aspiration (23.26%). The expression of CD45, a 
lymphocyte marker that was used as a negative selection marker, was very low in all of the cells 
(<6.12%). 
Osteogenic differentiation potential 
In the previously selected cells, osteogenic medium induced the cells to differentiate to 
osteoblast-like cells, which was characterized by increasing cellular ALP activities over time. 
HGFs were originally used as negative controls in this experiment. To our surprise, the HGFs 
that were used demonstrated a robust osteogenic potential demonstrated by the highest ALP 
activity in all samples (Figure 5). When focusing on the aBMSCs, cells from bone core had the 
highest ALP activity, followed by cells from extraction aspiration and osteotomy aspiration 
(Figure 6). Long bone BMSCs had a higher ALP activity than aBMSCs. 
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 CD73 (%) CD90 (%) CD105 (%) CD146 (%) CD45 (%) 
BMSC 
(iliac) 
99.96 99.43 99.19 93.70 0 
Ext  
(001) 
96.53 99.80 90.44 23.26 0.98 
Imp-BM 
(004) 
97.89 98.19 85.02 75.02 0 
Imp-BC 
(004) 
97.41 99.14 91.71 62.15 0.54 
HGF 98.80 97.53 96.88 80.13 6.12 
 
Table 2: Surface marker analysis using CD45, CD73, CD90, CD105 and CD146. BMSC represents human bone marrow stromal cells 
from iliac. Ext represents cells derived from extraction socket aspiration. 001 represents subject 001. Imp-BM represents bone marrow 
aspiration from implant osteotomy. Imp-BC represents bone core tissue from implant osteotomy. 004 represents subjects 004. HGF 
represents human gingival fibroblast.
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Figure 3: DNA contents on Day 0 and Day 3 of different samples. NT: no treatment. OM: osteogenic media. HGF2X represents 
human Gingival Fibroblast with 2X cell number. HGF1X represents human gingival fibroblast with 1X cell number. Ext-001: aspirate 
from extraction socket from subject 001. BC-004: bone core sample from subject 004. BM-004: bone marrow aspirate from osteotomy 
site from subject 004. R4: BMSCs from human iliac. DNA was measured in ng/ul. The mean of 3 or 4 replicates was presented 
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Figure 4: DNA fold changes. Rate of proliferation determined by the change of DNA content between Day 3 and Day 0, either under 
NT or OM treatment. NT represents the no treatment group. OM represents the osteogenic media group. HGF2X represents human 
Gingival Fibroblast with 2X cell number. HGF1X represents human gingival fibroblast with 1X cell number. Ext-001: aspirate from 
extraction socket from subject 001. BC-004: bone core sample from subject 004. BM-004: bone marrow aspirate from osteotomy site 
from subject 004. R4: BMSCs from human iliac.  
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Figure 5: ALP activities of 
different samples after 
normalized to total protein 
content (umol/ug/min). NT: no 
treatment. OM: osteogenic 
media. Ext-001: aspirate from 
extraction socket from subject 
001. BC-004: bone core sample 
from subject 004. BM-004: bone 
marrow aspirate from osteotomy 
site from subject 004. R4: 
BMSCs from human iliac. 
HGF1X represents human 
gingival fibroblast with 1X cell 
number, HGF2X represents 
human Gingival Fibroblast with 
2X cell number. The mean of 3 
or 4 replicates was presented. *: 
P < 0.05; **: P < 0.01; ***: P < 
0.001; ****: P < 0.0001.  
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Figure 6: Comparison of ALP activities of MSCs from alveolar bone and long bone (umol/ug/min). Figure 4 was reformatted after the 
removal of HGFs. NT: no treatment. OM: osteogenic media. Ext-001: aspirate from extraction socket from subject 001. BC-004: bone 
core sample from subject 004. BM-004: bone marrow aspirate from osteotomy site from subject 004. R4: BMSCs from human iliac. 
The mean of 3 or 4 replicates was presented. ****: P < 0.0001. 
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Discussion 
Historically MSCs haven been isolated from bone marrow of iliac crest15. Iliac crest harvest has 
been considered as the gold standard for obtaining MSCs, however, research has shown that the 
use of MSCs derived from different dental tissues may facilitate regeneration in animal models36. 
In this study different techniques were utilized to obtain MSCs through the use of bone core and 
marrow aspirate obtained during implant surgery as well as bone marrow aspirate obtained from 
extraction sockets. The results demonstrated different success rate of generating aBMSCs from 
different tissue sources, ranging from 40% to 80% with bone core samples being the most 
predictable sources in generating aBMSCs.  
Matsubara et al.31 also described the different success rates of generating aBMSCs from different 
techniques. They showed that extraction of wisdom teeth followed by marrow aspiration had 
greater success rates compared to dental implant aspiration after initial osteotomy. The authors 
suspected that this was related to the age of the subjects, as younger individuals were recruited 
for 3rd extraction compared to individuals recruited for implant surgery. The study did not 
examine bone core success rate at generating aBMSC. The results of the present study 
demonstrated that extraction aspiration success rates were slightly higher when compared to 
osteotomy aspiration, however, bone cores showed the highest success rates at generating 
aBMSC. This may be associated with the larger tissue volumes obtained from bone cores than 
those of marrow aspirates. 
In a study by Mason et al39 bone marrow samples were collected from 45 patients and aBMSCs 
were generated using three different techniques including; osteotomy aspiration, bone core, and 
bone core combined with osteotomy aspiration. The authors observed varying success rates with 
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the combination technique yielding a success rate of 100%, followed by the bone core technique 
at 97.5% and the osteotomy at 82% success rate. In comparison, success rates in the present 
study were lower with 40% for the osteotomy aspiration and 80% for the bone core technique. It 
is possible that the reduced success rates in the present study may be attributed to the small 
sample size of 12 patients. 
When comparing population doubling times (PDT), the results of this study demonstrated that 
aBMSCs from extraction aspirates had higher proliferation rates compared to those of osteotomy 
aspirates and bone cores (43.62h vs 54.72h vs 49.46h). When comparing the osteotomy aspirate 
versus bone core techniques, Mason et al.39 showed that proliferation was at least twice as fast 
for bone cores compared to osteotomy aspirates alone. These findings were supported by the 
present study in that bone core samples showed higher proliferation rates compared to the 
osteotomy aspirates however the rate was not twice as fast.  
MSC characterization was accomplished by studying different cell surface markers by using 
fluorescence-activating cell sorting in the three types of samples. All of the aBMSCs from 
extraction aspiration, osteotomy aspiration and bone core expressed high levels of CD 73 
(>96%), CD90 (> 98%), and CD105 (>85%). These results were also seen in long bone and 
HGFs. Mason et al.39 evaluated aBMSCs characteristics and found high levels of CD73, CD 90 
and CD105 in their samples. Matsubara et al.31 examined the difference between cell surface 
antigens of alveolar and iliac bone marrow stromal cells and showed that none of the cell surface 
antigens differed between the two groups. This was also the case in the current study with the 
exception that a large variance was observed in regard to CD146, in which iliac BMSCs showed 
higher expression than aBMSCs.   
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When comparing osteogenic potential Matsubara et al.31 showed that iliac BMSCs had similar 
ALP activity when compared to aBMSCs. The results of the current study suggest that ALP 
activity in iliac BMSCs was higher than that in cells from bone core, osteotomy aspiration, and 
extraction aspiration. Although this study used a small sample size, the results indicated that 
MSCs derived from jaw bones and long bones may have different properties. Originally, HGFs 
served as a negative control in the study. In unexpected results, the HGFs tested in this study 
demonstrated a robust proliferation potential and a much stronger ALP activity than each of the 
other cells. This difference may be attributable to the genetic background of this specific donor. 
Another possible explanation is that MSCs can also be found in gingival tissues41. In the future, 
it may be interesting to study the regenerative potential of HGFs. 
Several limitations were noted within this study. The sample size consisted of only 12 subjects, 
which is not an adequate size to achieve any statistical relevance. Although the study obtained 
samples in a standardized method, errors may possibly have occurred during collection, 
transportation, and/or analysis of the samples. Due to the small sample size it was not possible to 
evaluate the effects of sex, age, and health status on generating aBMSCs from different tissue 
sources. In addition, there was no attempt to account for differences in bone density among 
samples, grafted versus non grafted sites, maxilla versus mandible, and bone core volume. 
Another limitation was that in vivo bone formation of the MSCs obtained from the patients was 
not tested. It is also important to note that MSC can be obtained from PDL cells from during 
extraction of 3rd molars35,42,43 and from the dental pulp33. Finally, this study did not compare the 
differences between aBMSCs with MSCs from other dental tissues. 
Overall, this study compared three different techniques to obtain aMBSCs: extraction socket 
aspiration, osteotomy aspiration and bone core digestion. Further research is required to evaluate 
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the potential use of aBMSCs in periodontal regeneration and other regenerative procedures in 
dentistry. 
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Conclusion 
This study compared three different methods to obtain aBMSCs, including: extraction socket 
aspiration, osteotomy aspiration and bone core digestion. Bone core samples obtained during 
implant surgery may be a more reliable source for generating aBMSCs than extraction socket 
aspiration and osteotomy aspiration. MSCs derived from different methods may have different 
characteristics in regard to proliferation, differentiation potential and cell surface markers. 
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